Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AX-202 in Healthy Subjects and Patients With Mild to Moderate Chronic Plaque Psoriasis
NCT05965089Phase 1Completed
- Sponsor
- Arxx Therapeutics
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing AX-202 with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events, Safety and Tolerability by Physical Examinations and 4 more. Started Apr 2023; status: completed.
02
Drugs
AX-202
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05965089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965089.